Polypeptides that are being discovered by the biotechnology industry hold great promise as new drug candidates to target specific disease symptoms.
However, polypeptide drugs are rapidly degraded by proteolytic enzymes and neutralized by antibodies, among other shortcomings. This reduces their half-life and circulation time, thereby limiting their therapeutic effectiveness.
Pegylation of polypeptide drugs protects them and improves their pharmacodynamic and pharmacokinetic profiles.
The pegylation process attaches repeating units of polyethylene glycol (PEG) to a polypeptide drug. For the past 30 years, scientists have improved various chemistries to build PEG polymers and attach them to a polypeptide drug of choice.
Among the first pegylated drugs approved by the FDA in the early 1990s were pegaspargase for leukemia and pegademase for severe combined immunodeficiency disorder. More recently, pegylated drugs for the treatment of hepatitis C, acromegaly, rheumatoid arthritis, neutropenia, various cancers, wound healing, and other disorders either have been approved or are undergoing clinical trials.
Researchers will continue to perfect the chemistries employed in pegylation to develop more polypeptide therapeutic products.
Protein and peptide drugs hold great promise as therapeutic agents. However, many are degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate neutralizing antibodies and have a short circulating half-life. Pegylation, the process by which polyethylene glycol chains are attached to protein and peptide drugs, can overcome these and other shortcomings. By increasing the molecular mass of proteins and peptides and shielding them from proteolytic enzymes, pegylation improves pharmacokinetics. This article will review how PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
EJNMMI Research Open Access 08 July 2023
Signal Transduction and Targeted Therapy Open Access 11 May 2023
Nature Communications Open Access 27 April 2023
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Clark, A. Formulation of proteins and peptides for inhalation. Drug Deliv. Syst. Sci. (In the press).
Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459–476 (2002). An excellent review that covers the chemistry and synthesis of first- and second-generation pegylation processes.
Mateo, C. et al. Removal of amphipathic epitopes from genetically-engineered antibodies: production of modified immmunoglobulins with reduced immunogenicity. Hybridoma. 19, 436–471 (2000).
Lyczak, J. B. & Morrison, S. L. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein. Arch. Virol. 139, 189–196 (1994).
Syed, S. et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 89, 3242–3252 (1997).
Allen, T. M. Liposomes: opportunities in drug development. Drugs 54 Suppl. 4, 8–14 (1997).
Sebeni, J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15, 57–88 (1998).
Bailon, P. & Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1, 352–356 (1998).
Zaplinsky, S. Harris, J. M. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 1–15 (San Francisco, 1997).
Gabizon, A. & Martin, F. Polyethylene glycol-coated liposomal doxorubicin. Drugs 54 Suppl. 4, 15–21 (1997).
Yamaoka, T., Tabata, Y. & Ikada, Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601–606 (1994).
Working, P. K. et al. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 45–57 (San Francisco, 1997).
Richter, A. W. & Akerblom, E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethyleneglycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70, 124–131 (1983).
Cheng, T. et al. Acclerated clearance of polethylene glycol modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 10, 520–528 (1999).
Davis, F. F. et al. Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 4, 169–173 (1978).
Davis, F. F. et al. In Peptide and Protein Drug Delivery (ed Lee, V. H. L.) 226–231 (Marcel Dekker, New York, 1990).
Nucci, M. L., Schorr, R. & Abuchowski, A. The therapeutic value of polyethylene glycol modified protein. Adv. Drug Deliv. Rev. 6, 133–151 (1991).
Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001). This article describes the pharmacodynamics and pharmacokinetics advantages of pegylation for clinical drugs.
Kozlowski, A. & Harris, J. M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 72, 217–224 (2001). A detailed review of the pharmaceutical uses of pegylated proteins as human therapeutics.
Monfardini, C. et al. A branched monomethoxypolyethylene glycol for protein modification. Bioconjug. Chem. 6, 62–69 (1995).
Koslowski, A., Charles, S. A. & Harris, J. M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419–429 (2001). A detailed discussion of the clinical development of pegylated interferon for treating hepatitis C.
Katre, N. V. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev. 10, 91–114 (1993).
Zaplinsky, S. & Lee, C. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 347–370 (Plenum Press, NewYork, 1992).
Kinstler, O. B. et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 996–1002 (1996).
Zaplinsky, S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16, 157–182 (1995).
Harris, J. M. Synthesis of polyethylene glycol derivatives. J. Macromol. Sci. Rev. C25, 325–373 (1985).
Dust, J. M, Fang, Z. H. & Harris, J. M. Proton NMR characteristics of polyethylene glycol and derivatives. Macromolecules 23, 3742–3746 (1990).
Bentley, M. D. & Harris, J. M. Polyethylene glycol aldehyde hydrates and related polymers and applications in modifying. US Patent 5, 990, 237 (1999).
Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990).
El Tayar, N. et al. Polyo-IFN-β conjugates. WO 99/55377 (1999).
Zaplinsky, S. et al. New detachable polyethylene glycol conjugates:Cysteine-cleavable lipopolymers regenerating natural phospholipid. Bioconjug. Chem. 10, 703–710 (1999).
Yokoyama, M. et al. Synthesis of polyethylene oxide with heterobifunctional reactive groups at its terminals by an anionic inititator. Bioconjug. Chem. 3, 275–276 (1992).
Bentley, M. D., Harris, J. M. & Kozlowski, A. Heterobifunctional polyethylene glycol derivatives and methods for their preparation. WO 126692A1 (2001).
Yamasaki, N., Matsuo, A. & Isobe, H. Novel polyethylene glycol derivatives for modification of proteins. Agric. Biol. Chem. 52, 2125–2127 (1988).
Veronese, F. M. & Caliceti, P. Branched and linear polyethylene glycol influence of the polymer structure on enzymological, pharmacokinetic and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 12, 196–207 (1997).
Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency. Clin. Immunol. Immunopathol. 76, S228–232 (1995)
Burnham N. L. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51, 210–218 (1994).
Hillman, B. C. & Sorensen, R. U. Management options: SCIDS with adenosine deaminase deficiency. Ann. Allergy 72, 395–404 (1994).
Hershfield, M. S. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 145–154 (Plenum Press, NewYork, 1992).
Keating, M. J. et al. L-asparaginase and PEG asparaginase — past, present, and future. Leuk. Lymphoma 10, 153–157 (1993).
Holle, L. M. Pegasparagase: an alternative. Ann. Pharmacother. 3, 616–624 (1997).
Physicians' Desk Reference, 53 edition 2600–2601 (Thomson PDR, Montvale, New Jersey, 1999).
Liang, J. T. et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann. Intern. Med. 132, 296–305 (2000).
Grace, M. et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J. Interferon. Cytokine. Res. 21, 1103–1115 (2001).
Glue, P. et al. PEG-interferon-α2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatology 30, 189A (1999).
Linday, K. L. et al. A randomized double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395–403 (2001).
O'Brien, C. et al. A double-blind, mult-icenter randomized, parallel dose-comparison study of six regimens of 5kD linear peginterferon α-2a compared with Roferon-A in patients with chronic hepatitis C. Antivir. Ther. 4, 15 (1999).
Bailon, P. et al. Pharmacological properties of five polyethylene glycol conjugates of interferon α-2a. Antivir. Ther. 4, 27 (1999).
Algranati, N. E., Sy, S. & Modi, M. A branched methoxy 40 kDa polyethylene glycol moiety optimizes the pharmacokinetics of PEG–IFN. Hepatology 30, 190A (1999).
Zeuzem, S. et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666–1672 (2000).
Heathcote, E. J. et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673–1680 (2000).
Liang, J. T. et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296–305 (2000).
McHutchinson, J. G. et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485–1492 (1998).
Poynard, T. et al. Randomized trial of interferon α-2b plus ribavirin for 48 weeks versus interferon α-2b placebo for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426–1432 (1998).
Sulkowski, M. S. et al. Pegylated interferon α-2a and ribavirin combination therapy for chronic hepatitis C. Gastroenterology 118, 950 (2000).
Manns, M. P. et al. Peginterferon α-2b plus ribavirin compared to interferon α-2b plus ribavirin for the treatment of chronic hepatitis C. Lancet 358, 958–965 (2001).
Fried, M. W. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002).
Drake W. M. et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur. J. Endocrinol. 145, 451–456 (2001).
Van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001).
Edwards, C. K. PEGylated recombinant human soluble tumor necrosis factor receptor type I. Ann. Rheum. Dis. 58, 173–181 (1999).
Moreland, L. W. et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27, 601–609 (2000).
Choy E. H. et al. Efficacy of a novel pegylated humanized anti-tnf fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded randomized dose-escalating trial. Rheumatology 41, 1133–1137 (2002).
Crawford, J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev. 28, 7–11 (2002).
Bence, A. K. & Adams, V. R. Pegfilgrastim: a new therapy to prevent neutropenic fever. J. Am. Pharm. Assoc. (Wash) 42, 806–808 (2002).
Gordon, A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312–3322 (2001).
Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95–99 (2002).
Zhao, X. & Harris, M. J. Novel degradable polyethylene glycol hydrogels for controlled release of protein. J. Pharm. Sci. 87, 1450–1458 (1998).
Gillinov, A. M. & Lytle, B. W. A novel synthetic sealant to treat air leaks at cardiac reoperation. J. Card. Surg. 16, 255–257 (2001). An overview of the synthesis, characterization and potential uses of pegylated hydrogels
Wain, J. C. et al. Trial of a novel synthetic sealant in preventing air leaks after lung resection. Ann. Thorac. Surg. 71, 1623–1628 (2001).
Ferland, R., Mulani, D. & Campbell, P. K. Evaluation of a sprayable polyethylene gylcol adhesion barrier in a porcine efficacy model. Human Reprod. 16, 2718–2723 (2001).
Hinds, K. D. & Skim, S. W. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54, 505–530 (2002).
Weir, A. N. et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30, 512–516 (2002)
Rocca, M. et al. Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischemia/reperfusion injury. Int. J. Artif. Organs. 19, 730–734 (1996).
Calvo, P. et al. Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157–1165 (2001).
Shi, N. et al. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18, 1091–1095 (2001).
The amount of time it takes for one-half of a drug dose to be lost through biological processes.
- SHELF LIFE
The amount of time a stored drug retains its activity.
Phospholipid capsules that protect enclosed drugs from degradation.
- RETICULOENDOTHELIAL SYSTEM
A community of phagocytic cells of the body, located primarily in the spleen, liver and lymph nodes, that protect against infection.
A complex series of blood proteins whose actions augment the work of antibodies to destroy bacteria, produce inflammation and regulate immune reactions.
The movement of drugs throughout the body, including their absorption, distribution, metabolism and excretion, and the mathematical models that describe these actions.
Changes in measurable clinical parameters related to a drug, such as increase in antitumour activity, decrease in nausea, or decrease in viral load.
PEG with two terminal hydroxyl groups that lead to crosslinking and loss of activity.
PEGs with two different terminal groups, making them capable of performing different functions.
A disease characterized by abnormal enlargement of the skull, jaw, hands and feet, which is caused by excessive secretion of growth hormone by the pituary gland.
About this article
Cite this article
Harris, J., Chess, R. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2, 214–221 (2003). https://doi.org/10.1038/nrd1033
This article is cited by
EJNMMI Research (2023)
Nature Reviews Bioengineering (2023)
Nature Communications (2023)
Signal Transduction and Targeted Therapy (2023)
PEGylated bis-indolyl polyurethane dendrimers with anti-cancer activity as carriers for doxorubicin to treat lung cancer cells
Chemical Papers (2023)